(IN BRIEF) Roche has revealed that Dr. Hans Clevers, Head of Pharma Research and Early Development and board member since 2019, will retire from his pRED role at the end of August, though he will continue leading the Institute of … Read the full press release →
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Switzerland, Technology
Tagged appointment, Barbara Schädler, Board of Directors, corporate executive committee, COVID-19, Group Communications, Hans Clevers, Institute of Human Biology, Johannes Clevers, ledership, Pharma Research and Early Development, pRED, retirement, Roche, succession planning, Thomas Schinecker